EuroSIVA in Abu Dhabi: A Successful First Step ✨
On 14 September 2025, EuroSIVA had the privilege of participating in the Abu Dhabi Annual Anesthesia Congress (ADAAC), organized in conjunction with the Euro-Abu Dhabi Intensive Care Congress. For the first time in the Middle East, we hosted a TIVA/TCI Workshop at the Conrad Abu Dhabi Etihad Towers. The program included lectures on pharmacokinetics, pharmacodynamics, EEG monitoring, and drug interactions, as well as sessions on PK/PD modeling, TCI in special populations (children, elderly, obese), and practical exercises with TCI pumps and the TIVATrainer software. In addition to the workshop, EuroSIVA also contributed to the main scientific program with a symposium that addressed key aspects of TIVA and TCI: Why and how to do TIVA with TCI – Dr. Francisco A. Lobo Drug interactions – Dr. Frank Engbers The Eleveld universal PK/PD model for propofol – Dr. Hugo Vereecke Participants from the region and beyond joined these sessions, engaging with an international panel of experts: Dr. Francisco A. Lobo (UAE) –
EuroSIVA 2025: A Historic Gathering of Intravenous Anaesthesia Experts in Buenos Aires
For the first time since its foundation in 1998, EuroSIVA – the European Society for Intravenous Anaesthesia – will host its full-format event outside Europe. From May 15 to 17, 2025, Buenos Aires will welcome leading anaesthesiologists, researchers, and clinicians from around the world for a three-day conference fully dedicated to Total Intravenous Anaesthesia (TIVA). A Milestone in Anaesthesia Education EuroSIVA has been a key player in education and research in intravenous anaesthesia pharmacology. This year’s event at Palais Rouge in Buenos Aires marks an exciting expansion of its global reach. The conference will include keynote lectures, interactive workshops, and live clinical case discussions, focusing on TIVA, Target-Controlled Infusion (TCI), and advanced perioperative monitoring. This event is part of EuroSIVA on Tour, a new initiative bringing intravenous anaesthesia education beyond Europe. Other activities include EuroSIVA’s participation in ADAAC 2025 – the leading anaesthesia educational event in the Gulf Region. Programme Highlights The agenda will cover a wide range of topics
EuroSIVA Joins the Leading Anesthesia Educational Event in the Gulf Region: ADAAC 2025
EuroSIVA is proud to announce its participation in the Abu Dhabi Annual Anesthesia Congress (ADAAC), the premier educational event for anesthesiologists in the Gulf region, organized in conjunction with the Euro-Abu Dhabi Intensive Care Congress. For the first time in the Middle East, EuroSIVA will host an exclusive Total Intravenous Anesthesia (TIVA/TCI) Workshop on 14 September 2025 at Conrad Abu Dhabi Etihad Towers, UAE. The workshop agenda includes plenary lectures on pharmacokinetics, pharmacodynamics, EEG monitoring, and drug interactions, as well as focused sessions on PK/PD modeling, TCI in special populations (children, elderly, obese), and practical exercises with TCI pumps and TIVATrainer software. Participants will have the opportunity to learn from leading international experts in the field: Dr. Francisco A. Lobo (UAE) – EuroSIVA Chairman and Editor-in-Chief of Journal of Clinical Monitoring and Computing Dr. Siarhei Kastsiauchenka (UAE) – Anesthesiologist at Cleveland Clinic Abu Dhabi Dr. Frank Engbers (Netherlands) – EuroSIVA secretary and Developer of TIVATrainer and LabelSyringe Dr. Hugo Vereecke
Thank you to our Sponsors for supporting EUROSIVA Lisbon 2025!
We are pleased to express our deepest gratitude to Fresenius, Masimo, Neurowaves, and BD for their generous support of Lisboa 2025 – Make TIVA Simple Again, our upcoming postgraduate course on IV Anesthetic Pharmacology and Perioperative Monitoring. The event will take place on May 23–24, 2025, at the Main Auditorium, Edifício Egas Moniz, Faculdade de Medicina de Lisboa. This high-level academic gathering has been awarded 15 CME credits by the European Accreditation Council for Continuing Medical Education (EACCME), underscoring the educational value and relevance of the program. Thanks to our sponsors, we are able to bring together leading experts in intravenous anesthesia and perioperative care to share cutting-edge insights, foster interactive learning, and contribute to the continuous professional development of anesthesiologists and critical care providers. 📝 Registration is now open: http://eurosiva.eu/registration We look forward to welcoming you in Lisbon for two days of stimulating lectures, practical knowledge, and collaborative exchange. Once again, thank you to Fresenius, Masimo, Neurowaves, and BD
Eurosiva Lisbon 2025 Awarded 15 CMEs by EACCME®
We are pleased to announce that the Eurosiva Lisbon 2025 postgraduate course on IV Anesthetic Pharmacology and Perioperative Monitoring has been awarded 15 CME credits by the European Accreditation Council for Continuing Medical Education (EACCME®). This accreditation underscores the course’s high educational value for anesthesiologists looking to enhance their knowledge and skills in Total Intravenous Anesthesia (TIVA). By attending, participants will not only gain cutting-edge insights into IV anesthetic pharmacology but also earn valuable CME credits to advance their professional development. 📅Event Details: Dates: May 23-24, 2025 Location: Lisbon, Portugal Registration: http://eurosiva.eu/registration Additionally, this year’s Eurosiva Lisbon course takes place immediately before the ESAIC Euroanaesthesia Congress, making it an excellent opportunity to combine both educational experiences in one trip. Participants can deepen their TIVA expertise at Eurosiva and then continue their learning journey at one of the largest anesthesia congresses in the world.Register now and take advantage of this unique opportunity to expand your expertise, connect with international experts, and
Wintermeeting 2024 : Stefan Schraag
The different models implemented in TCI:how it happend and who is responsible Stefan Schraag Saturday 10:30-11:00 Who safeguards PK models? It is a tricky task for most to develop a pharmacokinetic model. It gets even more difficult to publish one without any typos. And then, once you have achieved that, what to do with it and how? This is one of the questions surrounding the governance of pharmacokinetic and pharmacodynamic research and scientific output when it informs medical device development and, ultimately, patient care. Since its inaugural incarnation in 1996, Target Controlled Infusion of propofol is such an example of a patient facing class 3 medical device supported by a pharmacokinetic model. Without going through the details of regulatory approval and post-market surveillance as demanded by the new Medical Device Regulations in Europe, I will discuss a few key questions that have been coming up over the last 25 years on TCI, its devices and model implementations. A great place
Wintermeeting 2024: Nick Sutcliffe
Why Total Intravenous Anaesthesia (TIVA) An overview on aspects of patient outcome, oncology, and the environment. Nick Sutcliffe Friday 19 January 8:30-9:00 Introduction The safety of surgery under anaesthesia has improved markedly over the last century. New drugs and improved equipment have resulted in more accurate dosing and reduced side effects. As mortality has improved, focus has shifted to also include non-lethal postoperative complications such as nausea, vomiting, pain, and cognitive dysfunction. Similarly, it is no longer sufficient to consider only immediate survival after surgery, but also longer-term issues such as cancer recurrence, quality of life and cognitive decline following surgery under anaesthesia. Propofol based TIVA has several potential advantages over volatile based anaesthesia (VBA), for both the patient and operating room staff, as well as environmental benefits. Evidence is accumulating to support the use of TIVA over VBA, in terms of improved patient outcomes, less toxicity in the local environment and less effect on the global environment relating to
Wintermeeting 2024:Francisco Lobo
Multimodal anesthesia and multimodal sedation: is two times one more than two? Francisco Lobo Friday 19 January 10:30-11:00 The state of General Anesthesia comprises unconsciousness, amnesia, analgesia/antinociception and immobility accompanied by physiological stability. Classically, this drug-induced reversible state has been achieved with the use of basic interactions between hypnotic drugs, opioids and muscular relaxants; the current balanced general anesthesia is usually based on an hypnotic drug for induction, volatile agent of intravenous drug for maintenance and opioids administered by boluses or as an infusion while muscle relaxation and paralysis may be achieved with the interaction between these drugs or supplemented by muscle relaxants. A new paradigm has been suggested involving more drugs than this basic triple cocktail. This multimodal general anesthesia approach is based on the ideas that: additional drugs acting in multiple neuronal pathways by different mechanisms may contribute to optimize the nociception-antinociception balance; the synergic and additive interactions between different drugs at lower doses will decrease the side